Do oral tirzepatide tablets work for weight loss?

The misconception: 'oral tirzepatide' exists and can be ordered

The most common misunderstanding around this topic is that an oral version of tirzepatide is already available, either from online sellers or as a compounded product. It is not. Tirzepatide's licensed route of administration is subcutaneous injection, and Eli Lilly has not received regulatory approval for an oral tirzepatide formulation from the MHRA, the FDA, or any comparable regulator as of the date this page was written. If you want to understand what oral tirzepatide actually refers to and where the research currently stands, our page on oral tirzepatide sets out the science and the regulatory position clearly. Products marketed as oral tirzepatide drops, capsules or lozenges through social media or unverified websites are not licensed medicines. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss products sold online, and the absence of a prescription requirement is a clear signal that something is wrong. If you want to know more about how the licensed injectable tirzepatide works at a biological level, our guide to tirzepatide's mechanism covers the dual GIP and GLP-1 receptor pathway in plain terms.

It is worth being equally clear about what IS available as a licensed oral option. Wegovy tablets, approved by the MHRA on 11 June 2026, are an oral GLP-1 medicine, but they contain semaglutide, not tirzepatide. The two medicines share a drug class but are chemically distinct, with different receptor profiles and different trial histories.

Why tirzepatide is harder to put in a tablet than it might sound

Getting large peptide molecules across the gut wall reliably is a genuine pharmaceutical challenge. Oral semaglutide tablets use an absorption enhancer called SNAC to move the drug through the stomach lining, and even then the dose needed orally (up to 25 mg daily) is far higher than the injected maintenance dose (2.4 mg weekly), because oral bioavailability is much lower. Tirzepatide has a different molecular structure and size profile; the same SNAC approach does not straightforwardly transfer. Eli Lilly is researching oral delivery of tirzepatide, but no phase-3 trial data for an oral tirzepatide weight-management formulation has been published. That is not a reason to doubt tirzepatide's effectiveness in its current form, the SURMOUNT-1 trial, published in the New England Journal of Medicine, recorded the largest average weight reductions of any single licensed medicine in the UK. It is simply an honest account of where the science is right now. People searching specifically for tirzepatide oral drops will find that no licensed product matches that description.

What your options genuinely are in the UK right now

If you are looking for a licensed, evidence-backed weight-loss medicine available from a regulated UK pharmacy, there are two injections and one tablet currently available. The Mounjaro injection (tirzepatide) and the Wegovy injection (semaglutide) are both licensed subcutaneous once-weekly treatments. Since June 2026, Wegovy tablets offer a genuinely needle-free option for people who prefer not to inject, though that is semaglutide rather than tirzepatide, and the two have different trial evidence behind them. A full comparison of what is available is on our weight-loss treatments page. If you want to understand how long tirzepatide takes to produce results in its licensed form, or explore Mounjaro in detail, those pages set out the evidence clearly. All three medicines are prescription-only under UK law, a prescriber assesses your health history, current medicines, BMI and any relevant conditions before deciding whether treatment is appropriate, and at what starting point. That clinical review is not a formality; it is what makes these medicines safe to use. According to NICE guidance TA1026, tirzepatide is recommended for adults with a BMI of 35 or above alongside at least one weight-related condition, with lower thresholds applying for some ethnic backgrounds under UK guidance. Private treatment, including through a GPhC-registered pharmacy like ours, follows the licensed eligibility criteria set out in the medicine's UK authorisation rather than the NHS phased rollout, so more people may qualify privately than currently qualify for NHS prescribing. A consultation lets a prescriber look at your individual picture, not a checkbox list. How to start that conversation is straightforward, you can read about who reviews consultations at nume, or speak to our prescribers directly. There is no long wait and no referral needed.

A note on cost and what to watch for

One reason people search for oral tirzepatide is cost. Injectable Mounjaro pens represent a monthly outlay, and the appeal of a cheaper-sounding oral alternative is understandable. The honest answer is that no licensed cheaper oral tirzepatide exists, and products priced as though they were a bargain version of a prescription medicine are almost certainly not what they claim. Understanding Mounjaro's real cost in the UK is a more useful starting point than looking for alternatives that are not yet real. For anyone ordering around a busy period (say, a payday order or before a bank-holiday weekend) knowing the actual dispatch and delivery timeline for genuine prescription medicine is more practically useful than any headline price. One transparent price that includes consultation, prescription, and next-working-day delivery is a simpler calculation than a low number that excludes clinical oversight. The right question for a prescription medicine is not which option costs least, but which option is genuinely licensed, clinically reviewed, and dispensed from a pharmacy you can verify on the GPhC register.